Abstract
Keywords
Abbreviations:
ACE2 (angiotensin-converting enzyme 2 receptor), Ang II (angiotensin II), Ang1,7 (angiotensin1,7), AT2 (angiotensin II receptor type 2), BMI (body mass index), COVID-19 (Coronavirus disease 2019), POP (prolyl oligopeptidase), PRCP (prolyl carboxypeptidases), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), RAS (renin-angiotensin system), VITT (vaccine-induced immune thrombotic thrombocytopenia)1. Introduction
- Wu C.
- Chen X.
- Cai Y.
- Xia J.
- Zhou X.
- Xu S.
- Huang H.
- Zhang L.
- Zhou X.
- Du C.
- Zhang Y.
- Song J.
- Wang S.
- Chao Y.
- Yang Z.
- Xu J.
- Zhou X.
- Chen D.
- Xiong W.
- Xu L.
- Zhou F.
- Jiang J.
- Bai C.
- Zheng J.
- Song Y.
- Angeli F.
- Marazzato J.
- Verdecchia P.
- Balestrino A.
- Bruschi C.
- Ceriana P.
- Chiovato L.
- Dalla Vecchia L.A.
- De Ponti R.
- Fanfulla F.
- La Rovere M.T.
- Perego F.
- Scalvini S.
- Spanevello A.
- Traversi E.
- Visca D.
- Vitacca M.
- Bachetti T
2. Conversion of angiotensin II to angiotensin1,7
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Maier C.
- Schadock I.
- Haber P.K.
- Wysocki J.
- Ye M.
- Kanwar Y.
- Flask C.A.
- Yu X.
- Hoit B.D.
- Adams G.N.
- Schmaier A.H.
- Bader M.
- Batlle D
3. Changes in angiotensinases
- Wu C.
- Chen X.
- Cai Y.
- Xia J.
- Zhou X.
- Xu S.
- Huang H.
- Zhang L.
- Zhou X.
- Du C.
- Zhang Y.
- Song J.
- Wang S.
- Chao Y.
- Yang Z.
- Xu J.
- Zhou X.
- Chen D.
- Xiong W.
- Xu L.
- Zhou F.
- Jiang J.
- Bai C.
- Zheng J.
- Song Y.
- Angeli F.
- Marazzato J.
- Verdecchia P.
- Balestrino A.
- Bruschi C.
- Ceriana P.
- Chiovato L.
- Dalla Vecchia L.A.
- De Ponti R.
- Fanfulla F.
- La Rovere M.T.
- Perego F.
- Scalvini S.
- Spanevello A.
- Traversi E.
- Visca D.
- Vitacca M.
- Bachetti T
- Kehoe K.
- Noels H.
- Theelen W.
- De Hert E.
- Xu S.
- Verrijken A.
- Arnould T.
- Fransen E.
- Hermans N.
- Lambeir A.M.
- Venge P.
- Van Gaal L.
- De Meester I.
- Kehoe K.
- Noels H.
- Theelen W.
- De Hert E.
- Xu S.
- Verrijken A.
- Arnould T.
- Fransen E.
- Hermans N.
- Lambeir A.M.
- Venge P.
- Van Gaal L.
- De Meester I.
- Kehoe K.
- Noels H.
- Theelen W.
- De Hert E.
- Xu S.
- Verrijken A.
- Arnould T.
- Fransen E.
- Hermans N.
- Lambeir A.M.
- Venge P.
- Van Gaal L.
- De Meester I.

4. Angiotensin II accumulation in the acute phase of SARS-CoV-2 infection
- Liu Y.
- Yang Y.
- Zhang C.
- Huang F.
- Wang F.
- Yuan J.
- Wang Z.
- Li J.
- Li J.
- Feng C.
- Zhang Z.
- Wang L.
- Peng L.
- Chen L.
- Qin Y.
- Zhao D.
- Tan S.
- Yin L.
- Xu J.
- Zhou C.
- Jiang C.
- Liu L.
- Angeli F.
- Marazzato J.
- Verdecchia P.
- Balestrino A.
- Bruschi C.
- Ceriana P.
- Chiovato L.
- Dalla Vecchia L.A.
- De Ponti R.
- Fanfulla F.
- La Rovere M.T.
- Perego F.
- Scalvini S.
- Spanevello A.
- Traversi E.
- Visca D.
- Vitacca M.
- Bachetti T
- Tukiainen T.
- Villani A.C.
- Yen A.
- Rivas M.A.
- Marshall J.L.
- Satija R.
- Aguirre M.
- Gauthier L.
- Fleharty M.
- Kirby A.
- Cummings B.B.
- Castel S.E.
- Karczewski K.J.
- Aguet F.
- Byrnes A.
- Consortium G.T.
- Laboratory D.A.
- Crackower M.A.
- Sarao R.
- Oudit G.Y.
- Yagil C.
- Kozieradzki I.
- Scanga S.E.
- Oliveira-dos-Santos A.J.
- da Costa J.
- Zhang L.
- Pei Y.
- Scholey J.
- Ferrario C.M.
- Manoukian A.S.
- Chappell M.C.
- Backx P.H.
- Yagil Y.
- Penninger J.M
- Yamamoto K.
- Ohishi M.
- Katsuya T.
- Ito N.
- Ikushima M.
- Kaibe M.
- Tatara Y.
- Shiota A.
- Sugano S.
- Takeda S.
- Rakugi H.
- Ogihara T.
- Wu C.
- Chen X.
- Cai Y.
- Xia J.
- Zhou X.
- Xu S.
- Huang H.
- Zhang L.
- Zhou X.
- Du C.
- Zhang Y.
- Song J.
- Wang S.
- Chao Y.
- Yang Z.
- Xu J.
- Zhou X.
- Chen D.
- Xiong W.
- Xu L.
- Zhou F.
- Jiang J.
- Bai C.
- Zheng J.
- Song Y.
- Angeli F.
- Marazzato J.
- Verdecchia P.
- Balestrino A.
- Bruschi C.
- Ceriana P.
- Chiovato L.
- Dalla Vecchia L.A.
- De Ponti R.
- Fanfulla F.
- La Rovere M.T.
- Perego F.
- Scalvini S.
- Spanevello A.
- Traversi E.
- Visca D.
- Vitacca M.
- Bachetti T
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Bracke A.
- De Hert E.
- De Bruyn M.
- Claesen K.
- Vliegen G.
- Vujkovic A.
- van Petersen L.
- De Winter F.H.R.
- Hotterbeekx A.
- Brosius I.
- Theunissen C.
- Van Ierssel S.
- van Frankenhuijsen M.
- Vlieghe E.
- Vercauteren K.
- Van der Veken P.
- Hendriks D.
- Kumar-Singh S.
- De Meester I
5. Angiotensin II accumulation after COVID-19 vaccination (the "Spike effect")
Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine (Last access on date April 14, 2021 ).
Watanabe Y., Mendonca L., Allen E.R., Howe A., Lee M., Allen J.D., Chawla H., Pulido D., Donnellan F., Davies H., Ulaszewska M., Belij-Rammerstorfer S., Morris S., Krebs A.S., Dejnirattisai W., Mongkolsapaya J., Supasa P., Screaton G.R., Green C.M., Lambe T., Zhang P., Gilbert S.C. and Crispin M. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. BioRxiv. 2021.
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Wysocki J.
- Ye M.
- Rodriguez E.
- Gonzalez-Pacheco F.R.
- Barrios C.
- Evora K.
- Schuster M.
- Loibner H.
- Brosnihan K.B.
- Ferrario C.M.
- Penninger J.M.
- Batlle D
- Maier C.
- Schadock I.
- Haber P.K.
- Wysocki J.
- Ye M.
- Kanwar Y.
- Flask C.A.
- Yu X.
- Hoit B.D.
- Adams G.N.
- Schmaier A.H.
- Bader M.
- Batlle D
- Kehoe K.
- Noels H.
- Theelen W.
- De Hert E.
- Xu S.
- Verrijken A.
- Arnould T.
- Fransen E.
- Hermans N.
- Lambeir A.M.
- Venge P.
- Van Gaal L.
- De Meester I.
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/02-COVID-See-508.pdf (Accessed on May 31, 2022).
6. Conclusion
- Serfozo P.
- Wysocki J.
- Gulua G.
- Schulze A.
- Ye M.
- Liu P.
- Jin J.
- Bader M.
- Myohanen T.
- Garcia-Horsman J.A.
- Batlle D
- Angeli F.
- Marazzato J.
- Verdecchia P.
- Balestrino A.
- Bruschi C.
- Ceriana P.
- Chiovato L.
- Dalla Vecchia L.A.
- De Ponti R.
- Fanfulla F.
- La Rovere M.T.
- Perego F.
- Scalvini S.
- Spanevello A.
- Traversi E.
- Visca D.
- Vitacca M.
- Bachetti T
- Bracke A.
- De Hert E.
- De Bruyn M.
- Claesen K.
- Vliegen G.
- Vujkovic A.
- van Petersen L.
- De Winter F.H.R.
- Hotterbeekx A.
- Brosius I.
- Theunissen C.
- Van Ierssel S.
- van Frankenhuijsen M.
- Vlieghe E.
- Vercauteren K.
- Van der Veken P.
- Hendriks D.
- Kumar-Singh S.
- De Meester I
Declaration of Competing Interest
References
- COVID-19: ACE2 centric infective disease?.Hypertension. 2020; 76 (Dallas, Tex : 1979): 294-299
- The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.Eur J Intern Med. 2020; 76: 14-20
- The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later.Eur J Intern Med. 2021; 93: 28-34
- SARS-CoV-2 infection and ACE2 inhibition.J Hypertens. 2021; 39: 1555-1558
- Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern Med. 2020; 180: 934-943
- Gender differences in patients with COVID-19: focus on severity and mortality.Front Public Health. 2020; 8: 152
- Racial and gender-based differences in COVID-19.Front Public Health. 2020; 8: 418
- Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19.Eur J Intern Med. 2021; 89: 81-86
- Risk factors for severe and critically ill COVID-19 patients: a review.Allergy. 2021; 76: 428-455
- Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis.Diabetes Res Clin Pract. 2020; 166108346
- Severity of COVID-19: the importance of being hypertensive.Monaldi Arch Chest Dis. 2020; 90
- Electrocardiographic features of patients with COVID-19 pneumonia.Eur J Intern Med. 2020; 78: 101-106
- Letter to the editor: angiotensin-converting enzyme 2: an ally or a trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.Am J Physiol Heart Circ Physiol. 2020; 318: H1080-H1083
- Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2.Circ Res. 2020; 126: 1456-1474
- Angiotensin converting enzyme 2: a double-edged sword.Circulation. 2020; 142: 426-428
- SARS-CoV-2 vaccines: lights and shadows.Eur J Intern Med. 2021; 88: 1-8
- Prolyl endopeptidases.Cell Mol Life Sci. 2007; 64: 345-355
- Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry.Am J Physiol Cell Physiol. 2013; 304: C945-C953
- Evidence that prolyl endopeptidase participates in the processing of brain angiotensin.J Hypertens. 1991; 9: 631-638
- Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.Am J Physiol Ren. Physiol. 2012; 302: F1583-F1594
- Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation Is POP (Prolyloligopeptidase)-dependent and ACE2 (Angiotensin-converting enzyme 2)-independent.Hypertension. 2020; 75 (Dallas, Tex : 1979): 173-182
- Brain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II.Hypertension. 1982; 4 (Dallas, Tex : 1979): 178-184
- A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11.Life Sci. 1993; 52: 1461-1480
- Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney.J Biol Chem. 1978; 253: 5927-5931
- Prolyl carboxypeptidase mRNA expression in the mouse brain.Brain Res. 2014; 1542: 85-92
- Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19.Gastroenterology. 2020; 159 (e1): 1170-1172
- Prolylcarboxypeptidase promotes angiogenesis and vascular repair.Blood. 2013; 122: 1522-1531
- Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase.Biochem Biophys Res Commun. 2011; 405: 338-343
- Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II.J Mol Med. 2017; 95 (Berl): 473-486
- Prolylcarboxypeptidase: a cardioprotective enzyme.Int J Biochem Cell Biol. 2009; 41: 477-481
- Hypertension and the bradykinin system.Curr Hypertens Rep. 2009; 11: 178-181
- Prolylcarboxypeptidase gene expression in the heart and kidney: effects of obesity and diabetes.Cardiovasc Hematol Agents Med Chem. 2015; 13: 113-123
- Effect of aging on rat tissue peptidase activities.J Gerontol A Biol Sci Med Sci. 2003; 58: B792-B797
- Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction.Clin Chem. 2012; 58: 1110-1115
- Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects.PLoS One. 2018; 13e0197603
- The bariatric surgery patient–nutrition considerations.Aust Fam Physician. 2013; 42: 547-552
- Pro-opiomelanocortin and its processing enzymes associate with plaque stability in human atherosclerosis - tampere vascular study.Sci Rep. 2018; 8: 15078
- The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade.Curr Clin Pharmacol. 2010; 5: 89-95
- ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus.G Ital Cardiol (Rome). 2020; 21: 321-327
- Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.J Hypertens. 2020; 38: 1190-1191
- ACE2 down-regulation may act as a transient molecular disease causing RAAS dysregulation and tissue damage in the microcirculatory environment among COVID-19 patients.Am J Pathol. 2021; 191: 1154-1164
- Intoxication with endogenous angiotensin II: a COVID-19 hypothesis.Front Immunol. 2020; 11: 1472
- Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients.Expert Opin Pharmacother. 2022; 23: 235-242
- RAAS inhibitors and risk of COVID-19.N Engl J Med. 2020; 383: 1990-1991
- Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: an Italian registry.J Cardiovasc Dev Dis. 2022; 9: 15
- Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.Crit Care. 2020; 24: 290
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.Sci China Life Sci. 2020; 63: 364-374
- Ageing, ACE2 deficiency and bad outcome in COVID-19.Clin Chem Lab Med. 2021;
- Electrocardiographic features of patients with COVID-19: one year of unexpected manifestations.Eur J Intern Med. 2022; 95: 7-12
- Age-associated changes in the vascular renin-angiotensin system in mice.Oxid Med Cell Longev. 2016; 20166731093
- Age- and gender-related difference of ACE2 expression in rat lung.Life Sci. 2006; 78: 2166-2171
- Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.Aging Cell. 2020; 19
- Coordinating center -analysis working G, statistical methods groups-analysis working G, enhancing Gg, fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nida, biospecimen collection source site N, biospecimen collection source site R, biospecimen core resource V, brain bank repository-university of miami brain endowment B, leidos biomedical-project M, study E, genome browser data I, visualization EBI, genome browser data I, visualization-Ucsc genomics institute UoCSC, lappalainen T, regev A, ardlie KG, hacohen N and MacArthur DG. landscape of X chromosome inactivation across human tissues.Nature. 2017; 550: 244-248
- Downregulation of spinal angiotensin converting enzyme 2 is involved in neuropathic pain associated with type 2 diabetes mellitus in mice.Biochem Pharmacol. 2020; 174113825
- COVID-19, diabetes mellitus and ACE2: the conundrum.Diabetes Res Clin Pract. 2020; 162108132
- Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2 and heparan sulfate.BioRxiv. 2021; 2021 (01.09.): 426021
- Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure.Circ Res. 2016; 118: 1313-1326
- Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature. 2002; 417: 822-828
- Angiotensin-converting enzyme II in the heart and the kidney.Circ Res. 2006; 98: 463-471
- Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.Circ Heart Fail. 2009; 2: 446-455
- Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.Hypertension. 2006; 47 (Dallas, Tex : 1979): 718-726
- The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis.Front Immunol. 2015; 6: 387
- The C-terminal cleavage of angiotensin II and III is mediated by prolyl carboxypeptidase in human umbilical vein and aortic endothelial cells.Biochem Pharmacol. 2021; 192114738
- Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.Clin Chim Acta. 2022; 531: 4-11
- The counter regulatory axis of the lung renin-angiotensin system in severe COVID-19: pathophysiology and clinical implications.Heart Lung Circ. 2021; 30: 786-794
- COVID-19: European countries suspend use of oxford-AstraZeneca vaccine after reports of blood clots.BMJ. 2021; 372: n699
Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine (Last access on date April 14, 2021 ).
- Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.N Engl J Med. 2021; 384: 2092-2101
- Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.N Engl J Med. 2021; 384: 2124-2130
- Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older.JAMA Intern Med. 2021; 181: 1668-1670
- Comorbidities and symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related myocarditis and SARS-CoV-2 vaccine-related myocarditis: a review.Cureus. 2022; 14: e24084
- COVID-19 vaccine-induced myocarditis: case report with literature review.Diabetes Metab Syndr. 2021; 15102205
- Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: a case report and literature review.Cardiovasc Revasc Med. 2022; 38: 117-123
- Acute fulminant myocarditis After ChAdOx1 nCoV-19 vaccine: a case report and literature review.Front Cardiovasc Med. 2022; 9856991
- Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.BMJ Open. 2022; 12e059223
- Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis.J Cardiovasc Dev Dis. 2022; 9: 150
- Hypertension after COVID-19 vaccination.G Ital Cardiol. 2022; 23 (Rome): 10-14
Watanabe Y., Mendonca L., Allen E.R., Howe A., Lee M., Allen J.D., Chawla H., Pulido D., Donnellan F., Davies H., Ulaszewska M., Belij-Rammerstorfer S., Morris S., Krebs A.S., Dejnirattisai W., Mongkolsapaya J., Supasa P., Screaton G.R., Green C.M., Lambe T., Zhang P., Gilbert S.C. and Crispin M. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. BioRxiv. 2021.
- Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism.Hypertension. 2014; 64: 1368-1375
- SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.J Hematol Oncol. 2020; 13: 120
- Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine.Eur J Intern Med. 2021; 90: 111-113
- Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.Hypertension. 2010; 55 (Dallas, Tex : 1979): 90-98
- Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia.Am J Obstet Gynecol. 2006; 195: 162-171
- Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.Blood. 2011; 117: 3929-3937
- Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells.Hypertension. 2010; 56 (Dallas, Tex : 1979): 384-390
- COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion.(Corporate Authors(s))in: Proceedings of the United States Advisory Committee on Immunization Practices (US ACIP) COVID-19 vaccines work group conference, Atlanta, GA2021 (Author(s): US ACIP MeetingMay 12, 2021 Published June 23, 2021)
- Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.N Engl J Med. 2021; 384: 2124-2130
- Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia.N Engl J Med. 2021; 385: 720-728
- Clinical Features of vaccine-induced immune thrombocytopenia and thrombosis.N Engl J Med. 2021; 385: 1680-1689
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/02-COVID-See-508.pdf (Accessed on May 31, 2022).
- Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.Vaccine. 2021; 39: 6485-6491
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.Antivir. Res. 2020; 176104742
- Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.Cell Mol Life Sci. 2021; 78: 1501-1522
- In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats.Hypertension. 1992; 19 (Dallas, Tex : 1979): 692-696